Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism
Phase 4
Completed
- Conditions
- Hypogonadism
- Interventions
- Drug: Sustanon
- Registration Number
- NCT01107067
- Lead Sponsor
- Gulhane School of Medicine
- Brief Summary
The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 32
Inclusion Criteria
- Volunteers patients with hypogonadism
Exclusion Criteria
- Coronary heart disease
- Other pituitary/hypothalamic disorders or other non-hypogonadism diseases
- None was receiving vitamins, lipid-lowering drugs, or other medications known to interfere with PON1 activity, lipid profile, or gonadal function
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description testosterone replacement therapy Sustanon -
- Primary Outcome Measures
Name Time Method paraoxonase level after testosterone treatment
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain the decrease in paraoxonase 1 activity after testosterone replacement therapy in hypogonadism?
How does Sustanon compare to other testosterone formulations in modulating paraoxonase levels in hypogonadotropic hypogonadal patients?
Are there specific biomarkers that correlate with changes in paraoxonase 1 activity following testosterone treatment in male hypogonadism?
What adverse events are associated with Sustanon-induced changes in paraoxonase 1 activity in hypogonadism patients?
How do testosterone replacement therapies like Sustanon interact with other treatments for hypogonadism in terms of paraoxonase 1 modulation?
Trial Locations
- Locations (1)
Aydoğan AYDOĞDU
🇹🇷Ankara, Turkey
Aydoğan AYDOĞDU🇹🇷Ankara, Turkey